文献速递湿疹皮炎与荨麻疹银屑病与炎症性皮肤病

大麻素治疗慢性瘙痒的研究综述

Cannabinoids for the treatment of chronic pruritus: A review.
PubMed 文献 · J Am Acad Dermatol · 2020-01-25

本文综述大麻素治疗慢性瘙痒的机制与临床证据。内源性大麻素系统参与皮肤稳态及瘙痒、伤害感受、炎症与免疫反应调节;体外与动物模型提示其通过外周瘙痒神经纤维调控和中枢大麻素受体发挥作用。有限的人体研究因大麻素种类、疾病模型和给药方式差异而不一,但一致显示搔抓与症状显著减轻,涉及特应性皮炎、银屑病、干燥性湿疹、结节性痒疹、过敏性接触性皮炎及尿毒症性、胆汁淤积性瘙痒。

要点

  • 大麻素可能经外周瘙痒纤维与中枢受体两条途径缓解瘙痒
  • 人体研究一致显示慢性瘙痒患者搔抓与症状显著减轻
  • 难治性慢性瘙痒者在合法地区可考虑大麻素制剂作为辅助治疗

核心结论

  • 初步人体研究支持大麻素对慢性瘙痒的潜在获益,但需对照试验确认疗效并标准化治疗方案与适应证。
  • 对标准治疗无效的难治性慢性瘙痒患者,在合法地区可考虑大麻素制剂作为辅助治疗。

研究设计与样本

  • 综述,汇总体外与动物模型研究及人体研究,探讨大麻素对瘙痒的作用机制与临床证据。
  • 人体研究因所用大麻素、疾病模型和给药方式存在差异而受限。

主要发现

  • 体外与动物模型中最有力的证据支持大麻素通过调控外周瘙痒神经纤维及中枢大麻素受体发挥作用。
  • 人体研究一致显示慢性瘙痒患者搔抓与症状显著减轻。
  • 临床研究显示多种皮肤病(特应性皮炎、银屑病、干燥性湿疹、结节性痒疹、过敏性接触性皮炎)及系统性疾病(尿毒症性瘙痒、胆汁淤积性瘙痒)的瘙痒减轻。

临床怎么用

  • 对标准治疗无效的难治性慢性瘙痒患者,可在合法地区将大麻素制剂作为辅助治疗考虑。
  • 需开展对照试验以确认疗效并标准化治疗方案与适应证。

局限性

  • 人体研究有限,且因大麻素种类、疾病模型和给药方式不同而难以比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Medical marijuana is becoming widely available to patients in the United States, and with recreational marijuana now legalized in many states, patient interest is on the rise. The endocannabinoid system plays an important role in skin homeostasis in addition to broader effects on neurogenic responses such as pruritus and nociception, inflammation, and immune reactions. Numerous studies of in vitro and animal models have provided insight into the possible mechanisms of cannabinoid modulation on pruritus, with the most evidence behind neuronal modulation of peripheral itch fibers and centrally acting cannabinoid receptors. In addition, human studies, although limited due to differences in the cannabinoids used, disease models, and delivery method, have consistently shown significant reductions in both scratching and symptoms in chronic pruritus. Clinical studies have shown a reduction in pruritus in several dermatologic (atopic dermatitis, psoriasis, asteatotic eczema, prurigo nodularis, and allergic contact dermatitis) and systemic (uremic pruritus and cholestatic pruritus) diseases. These preliminary human studies warrant controlled trials to confirm the benefit of cannabinoids for treatment of pruritus and to standardize treatment regimens and indications. In patients who have refractory chronic pruritus after standard therapies, cannabinoid formulations may be considered as an adjuvant therapy where it is legal.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Avila C, Massick S, Kaffenberger BH, et al. Cannabinoids for the treatment of chronic pruritus: A review. J Am Acad Dermatol. 2020. PMID: 31987788. doi:10.1016/j.jaad.2020.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。